Search

Displaying results 2501 - 2510 of 10000 in total
  1. Drug

    Cenegermin

    go.drugbank.com/drugs/DB13926
    ApprovedInvestigational

    The prevalence of neurotrophic keratitis has been estimated to be less than five in 10,000 individuals. … [L4563] In particular, cenegermin was granted Priority Review designation, under which the FDA’s goal is to take action on an application within six months of application filing where the agency determines

  2. Drug

    Mexazolam

    go.drugbank.com/drugs/DB15489
    Investigational

    [A184910] The use of benzodiazepines in the treatment of anxiety is generally a second line measure.[A184910] … [A184910] Mexazolam's structure is similar to that of other benzodiazepines such as [oxazolam] and [cloxazolam].

  3. Drug

    Cinnarizine

    go.drugbank.com/drugs/DB00568
    ApprovedInvestigational

    Combination use of cinnarizine with other nootropics, such as [piracetam] resulted in enhanced effect of boosting brain oxygen supply. … Cinnarizine could be also viewed as a nootropic drug because of its vasorelaxating abilities (due to calcium channel blockage), which happen mostly in brain.

    Products: CN - 25
  4. Drug

    Zanubrutinib

    go.drugbank.com/drugs/DB15035
    ApprovedInvestigational

    Zanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with MCL,[ … [A187958] Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017.

  5. Drug

    Gadopiclenol

    go.drugbank.com/drugs/DB17084
    ApprovedInvestigational

    [A254002,A254017] In September 2022, the use of gadopiclenol was approved by the FDA. … [L43817] In 2006, the use of GBCAs was associated with the development of nephrogenic systemic fibrosis (NSF), a rare disorder characterized by the thickening and hardening of skin and subcutaneous tissues

  6. Drug

    Vatalanib

    go.drugbank.com/drugs/DB04879
    Investigational

    Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors.

  7. Drug

    Arotinolol

    go.drugbank.com/drugs/DB09204
    Investigational

    Arotinolol is an alpha- and beta-receptor blocker developed in Japan. It is a thiopropanolamine with a tertiary butyl moiety. It has been studied for its potential to be an antihypertensive therapy.

  8. Drug

    Flucytosine

    go.drugbank.com/drugs/DB01099
    ApprovedInvestigational

    A fluorinated cytosine analog that is used as an antifungal agent.

  9. Drug

    Urethane

    go.drugbank.com/drugs/DB04827
    ApprovedWithdrawn

    Urethane, formerly marketed as an inactive ingredient in Profenil injection, was determined to be carcinogenic and was removed from the Canadian, US, and UK markets in 1963.

  10. Drug

    Sertaconazole

    go.drugbank.com/drugs/DB01153
    Approved

    Sertaconazole nitrate is an antifungal medication of the imidazole class. It is available in topical formulations for the treatment of skin infections such as athlete's foot.